Compare NSRX & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSRX | EVAX |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | Israel | Denmark |
| Employees | 7 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.2M | 32.7M |
| IPO Year | N/A | 2020 |
| Metric | NSRX | EVAX |
|---|---|---|
| Price | $3.20 | $4.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $19.67 | $11.67 |
| AVG Volume (30 Days) | ★ 52.6K | 26.7K |
| Earning Date | 03-25-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $328.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.98 | $2.11 |
| 52 Week High | $9.99 | $12.15 |
| Indicator | NSRX | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 54.73 | 49.74 |
| Support Level | $2.04 | $3.93 |
| Resistance Level | $3.48 | $4.65 |
| Average True Range (ATR) | 0.25 | 0.22 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 63.64 | 38.07 |
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.